TransGLYCIT Generates Homogenous IgG Glycoforms

TransGLYCIT is a platform that enables specific IgG glycan remodeling and prepares antibodies with defined and homogenous glycoforms using fast and robust enzymatic workflows. With the optional FucosEXO 16™ enzyme, afucosylated antibodies can be obtained that enable direct comparison of antibodies with or without core fucose.

TransGLYCIT is available in the following product formats:

The Transglycosylation Workflow

  1. Deglycosylation
    The Fc N-glycans are trimmed to the core GlcNAc using the IgG-specific Immobilized GlycINATOR® (EndoS2) enzyme that hydrolyses all Fc glycoforms, including high-mannose, hybrid, complex and bisecting glycans. To obtain afucosylated glycoforms, the optional Immobilized FucosEXO™ 16 enzyme hydrolyzes the α1-6 linked core fucose.
  2. Transglycosylation
    The engineered glycosynthase TransINATOR™ catalyzes the transglycosylation reaction between the oxazoline reactive G0, G1, G2 or G2S2 glycoform and the core GlcNAc.


TransGLYCIT Product Information

TransGLYCIT is a platform technology for efficient transglycosylation of native IgG in three hours. The robust workflow transglycosylates the antibody Fc N-glycans using enzymatic remodeling, resulting in a homogenous pool of antibodies with a defined glycoform. The technology is available in kit formats to generate antibodies carrying the G0, G1, G2 or G2S2 glycan profile with the option to remove the core fucose using the TransGLYCIT Afucosylated kit. The enzymes in TransGLYCIT are expressed in E. coli and modified with His-tags. TransGLYCIT is provided in kits for processing of up to 1 mg of human IgG.

Unit Definition

TransGLYCIT transglycosylates ≥ 95% human IgG1 as measured by LC-MS.

Storage and Content

TransGLYCIT is shipped cold, and the content should be stored at different temperatures upon arrival. Do not freeze the product! TransGLYCIT is provided in kits containing sufficient material to transglycosylate up to 1 mg of IgG. TransGLYCIT is for R&D use only.

TransGLYCIT contains:

  • Immobilized GlycINATOR (TransGLYCIT)
    Immobilized GlycINATOR & Immobilized FucosEXO 16 (TransGLYCIT Afucosylated)
  • TransINATOR enzyme
  • Oxazoline glycoform G0, G1, G2 or G2S2
  • CaptureSelect™ spin column for purification
  • Human IgG1, IgG2 and IgG4
  • 3-hour workflow
  • Glycoform G0, G1, G2 or G2S2 is included
  • Optional defucosylation with FucosEXO 16
  • T1-G0A-010

    TransGLYCIT G0 Afucosylated 1 mg

    T1-G0A-0101,350.00Add to cart
  • T1-G1A-010

    TransGLYCIT G1 Afucosylated 1 mg

    T1-G1A-0101,350.00Add to cart
  • T1-G2A-010

    TransGLYCIT G2 Afucosylated 1 mg

    T1-G2A-0101,350.00Add to cart
  • T1-S2A-010

    TransGLYCIT G2S2 Afucosylated 1 mg

    T1-S2A-0101,350.00Add to cart

Product Documents



Popular FAQ

GlycINATOR is an IgG specific endoglycosidase that hydrolyzes complex, hybrid and high mannonse type glycans on the conserved Fc site on IgG.

Yes, the transglycosylation reaction can be performed on all subclasses of human IgG. The reaction is somewhat slower on IgG2 and longer incubation times may be necessary to obtain over 95% transglycosylation.

Unfortunately no, the enzyme requires trimming of the Fc-glycan using GlycINATOR to enable access to the core fucose substrate.

No, TransGLYCIT is based on IgG specific enzymes and will only transglycosylate IgG.

The TransGLYCIT platform is developed for transglycosylation of human IgG.


Find all FAQ here

Order TransGLYCIT

Place an order for TransGLYCIT or buy in our online Store


TransGLYCIT Brochure

TransGLYCIT Brochure

TransGLYCIT is a platform for transglycosylation of IgG.

Support Enzymes for Biopharmaceuticals


Contact our enzyme experts for support and technical questions.